Rocket Pharmaceuticals, Inc. (RCKT) Ownership
RCKT ownership summary
as of October 17, 2026- Institutions
- 91.8% of shares outstanding
- Insiders
- 3.18% of shares outstanding
- Shares outstanding
- 109.8M
- Float
- 87.6M shares available to trade
- Short interest
- 16.80% 15.0M shares short
- Days to cover
- 8.45 short interest up 1.4% vs prior month
- Institutions 91.82%
- Insiders 3.18%
- Other investors 5.00%
RCKT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LLC | 16.11% | 17.7M | $38.6M | — | June 30, 2026 |
| 2 | BlackRock Inc | 9.04% | 9.9M | $21.6M | +2.1M (+26.7%) | June 30, 2026 |
| 3 | Vanguard Portfolio Management, LLC | 5.29% | 5.8M | $12.7M | +1.1M (+23.9%) | June 30, 2026 |
| 4 | Citigroup Inc | 4.43% | 4.9M | $10.6M | −242,157 (−4.7%) | June 30, 2026 |
| 5 | Marshall Wace Asset Management Ltd | 3.67% | 4.0M | $8.8M | +990,547 (+32.6%) | June 30, 2026 |
| 6 | Millennium Management LLC | 3.64% | 4.0M | $8.7M | +882,220 (+28.3%) | June 30, 2026 |
| 7 | Newtyn Management LLC | 3.64% | 4.0M | $8.7M | +834,100 (+26.3%) | June 30, 2026 |
| 8 | Maverick Capital Ltd | 3.57% | 3.9M | $8.6M | +356,591 (+10.0%) | June 30, 2026 |
| 9 | Vanguard Capital Management, LLC | 3.45% | 3.8M | $8.2M | +8,651 (+0.2%) | June 30, 2026 |
| 10 | AQR Capital Management LLC | 3.08% | 3.4M | $7.4M | +316,232 (+10.3%) | June 30, 2026 |
| 11 | The Goldman Sachs Group Inc | 2.58% | 2.8M | $6.2M | +1.1M (+64.6%) | June 30, 2026 |
| 12 | Monaco Asset Management | 2.26% | 2.5M | $5.4M | +422,165 (+20.5%) | June 30, 2026 |
| 13 | Geode Capital Management, LLC | 2.16% | 2.4M | $5.2M | +181,473 (+8.3%) | June 30, 2026 |
| 14 | Federated Hermes Inc | 2.10% | 2.3M | $5.0M | +1.3M (+125.1%) | June 30, 2026 |
| 15 | JPMorgan Chase & Co | 1.81% | 2.0M | $4.3M | +1.2M (+149.7%) | June 30, 2026 |
| 16 | Jacobs Levy Equity Management, Inc. | 1.80% | 2.0M | $4.3M | +1.6M (+374.1%) | June 30, 2026 |
| 17 | State Street Corp | 1.66% | 1.8M | $4.0M | −2.7M (−59.4%) | June 30, 2026 |
| 18 | Dimensional Fund Advisors, Inc. | 1.03% | 1.1M | $2.5M | +837,236 (+290.4%) | June 30, 2026 |
| 19 | Morgan Stanley - Brokerage Accounts | 0.97% | 1.1M | $2.3M | −957,586 (−47.4%) | June 30, 2026 |
| 20 | Opaleye Management Inc | 0.91% | 1.0M | $2.2M | +45,000 (+4.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 16 holders added 13.2M shares and 3 cut 3.9M.
RCKT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.46% | 2.7M | $5.9M | — | August 31, 2026 |
| 2 | RTW Biotech Opportunities Ord | 2.33% | 2.6M | $5.6M | −11,091 (−0.4%) | December 31, 2025 |
| 3 | iShares Russell 2000 ETF | 2.17% | 2.4M | $5.2M | −27,456 (−1.1%) | September 30, 2026 |
| 4 | Vanguard Strategic Equity Inv | 1.55% | 1.7M | $3.7M | +526,892 (+45.0%) | June 30, 2026 |
| 5 | Vanguard Explorer Inv | 1.48% | 1.6M | $3.5M | +403,998 (+33.1%) | June 30, 2026 |
| 6 | Federated Hermes MDT Small Cap Core IS | 0.95% | 1.0M | $2.3M | +690,676 (+198.9%) | June 30, 2026 |
| 7 | Fidelity Small Cap Index | 0.90% | 985K | $2.1M | +2,330 (+0.2%) | July 31, 2026 |
| 8 | BlackRock Advantage Small Cap Core Instl | 0.90% | 983K | $2.1M | +55,696 (+6.0%) | August 31, 2026 |
| 9 | Fidelity Enhanced Small Cap Core ETF | 0.88% | 967K | $2.1M | +2,028 (+0.2%) | September 30, 2026 |
| 10 | abrdn Life Sciences Investors | 0.84% | 925K | $2.0M | +321,903 (+53.4%) | August 31, 2026 |
| 11 | Vanguard Strategic Small-Cap Equity Inv | 0.82% | 899K | $2.0M | −106,700 (−10.6%) | June 30, 2026 |
| 12 | iShares Russell 2000 Value ETF | 0.77% | 849K | $1.9M | +1,288 (+0.2%) | September 30, 2026 |
| 13 | iShares Biotechnology ETF | 0.76% | 836K | $1.8M | −6,336 (−0.8%) | September 30, 2026 |
| 14 | Bridge Builder Small/Mid Cap Value | 0.69% | 760K | $1.7M | +725,746 (+2,142.7%) | September 30, 2026 |
| 15 | HBM Healthcare Investments AG Ord | 0.62% | 676K | $1.5M | — | June 30, 2026 |
| 16 | Vanguard Russell 2000 ETF | 0.47% | 518K | $1.1M | +10,320 (+2.0%) | August 31, 2026 |
| 17 | Fidelity Extended Market Index | 0.43% | 477K | $1.0M | −2,565 (−0.5%) | August 31, 2026 |
| 18 | Schwab US Small-Cap ETF™ | 0.41% | 453K | $987,486 | +306 (+0.1%) | September 30, 2026 |
| 19 | Federated Hermes MDT Small Cap Growth IS | 0.39% | 433K | $942,996 | +203,542 (+88.9%) | June 30, 2026 |
| 20 | JPM Thmtcs Gentc Thrps C2 dist USD | 0.36% | 396K | $862,458 | +4,438 (+1.1%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
RCKT insider transactions
latest 16| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-02-18 | John Militello | Sell | $3.34 | 1,157 | $3,864 |
| 2026-02-13 | Gaurav Shah | Sell | $3.31 | 12,279 | $40,643 |
| 2026-02-13 | John Militello | Sell | $3.31 | 3,726 | $12,333 |
| 2026-02-13 | Martin Wilson | Sell | $3.31 | 12,253 | $40,557 |
| 2025-10-14 | John Militello | Sell | $3.96 | 28,918 | $114,515 |
| 2025-08-27 | Elisabeth Bjork | Buy | $3.41 | 10,000 | $34,100 |
| 2025-08-19 | John Militello | Sell | $3.00 | 361 | $1,083 |
| 2025-08-19 | Jonathan David Schwartz | Sell | $3.00 | 805 | $2,415 |
| 2025-08-19 | Martin Wilson | Sell | $3.00 | 588 | $1,764 |
| 2025-08-18 | John Militello | Sell | $3.06 | 699 | $2,139 |
| 2025-08-18 | Jonathan David Schwartz | Sell | $3.06 | 1,680 | $5,141 |
| 2025-08-18 | Martin Wilson | Sell | $3.06 | 1,004 | $3,072 |
| 2025-08-14 | John Militello | Sell | $3.02 | 7,043 | $21,270 |
| 2025-08-14 | Jonathan David Schwartz | Sell | $3.02 | 11,161 | $33,706 |
| 2025-08-14 | Martin Wilson | Sell | $3.02 | 12,109 | $36,569 |
| 2025-07-03 | Aaron Ondrey | Sell | $2.88 | 1,477 | $4,254 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
RCKT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns RCKT
Institutional investors own 91.8% of Rocket Pharmaceuticals's shares and insiders 3.18%. The largest holder is RTW INVESTMENTS, LLC with 16.11% of the shares (17.7M), as of June 30, 2026. Among the top 20 institutions, 16 added shares and 3 reduced their stake in the latest filings. Short interest is 16.80% of the float, or 8.45 days of average trading volume. The share count rose 5,182.8% since 2014.
Related: RCKT analyst forecast, RCKT key metrics. See the RCKT stock overview for the latest quote and news.
RCKT ownership FAQ
Who owns the most Rocket Pharmaceuticals stock?
The largest shareholders of Rocket Pharmaceuticals are RTW INVESTMENTS, LLC (16.11%), BlackRock Inc (9.04%), Vanguard Portfolio Management, LLC (5.29%), Citigroup Inc (4.43%), Marshall Wace Asset Management Ltd (3.67%).
What percentage of Rocket Pharmaceuticals is owned by institutions?
Institutions hold 91.8% of Rocket Pharmaceuticals's shares outstanding; insiders hold 3.18%.
Which funds own Rocket Pharmaceuticals?
The largest fund holders of Rocket Pharmaceuticals are Vanguard MStar Total Stk Mkt Idx Invest (2.46%), RTW Biotech Opportunities Ord (2.33%), iShares Russell 2000 ETF (2.17%), Vanguard Strategic Equity Inv (1.55%), Vanguard Explorer Inv (1.48%).
What is Rocket Pharmaceuticals's short interest?
15.0M shares of Rocket Pharmaceuticals were sold short, 16.80% of the float; at the average daily volume it would take 8.45 days to cover.
Are insiders buying or selling Rocket Pharmaceuticals?
Of the latest 16 reported insider transactions in Rocket Pharmaceuticals (since July 3, 2025), 1 were purchases and 15 were sales.
How many shares of Rocket Pharmaceuticals are outstanding?
Rocket Pharmaceuticals has 109.8M shares outstanding, of which 87.6M are in the public float.